¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"Y51"¿¡ ´ëÇÑ Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
5
ÆäÀÌÁö:
1
ÄÚµå
¿µ¹®
ÇѱÛ
Y51.0
Anticholinesterase agents
Ç×Äݸ°¿¡½ºÆ®¶óÁ¦Á¦
Y51.8
Centrally acting and adrenergic-neuron-blocking agents, NEC
´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁßÃß¼º ÀÛ¿ë ¹× ¾Æµå·¹³ÊÁ÷ ´º·Ð Â÷´ÜÁ¦
Y51
Drugs primarily affecting the autonomic nervous system
ÀÏÂ÷ÀûÀ¸·Î ÀÚÀ²½Å°æ°èÅë¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦
Y51.2
Ganglionic blocking drugs, NEC
´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ½Å°æÀý Â÷´Ü¾àÁ¦
Y51.9
Other and unspecified drugs primarily affecting the autonomic nervous system
±âŸ ¹× »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷ÀûÀ¸·Î ÀÚÀ²½Å°æ°èÅë¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
ÄÚµå
¿µ¹®
ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½